Karyopharm Therapeutics reported $589K in Cost of Sales for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
TG Therapeutics TGTX:US 292K 144K
Abbott ABT:US $ 4423M 520M
Abbvie ABBV:US $ 4341M 157M
Amgen AMGN:US $ 1609M 28M
Astrazeneca AZN:US 3.82B 1.63B
AstraZeneca AZN:LN 3824M 1631M
Biocryst Pharmaceuticals BCRX:US $ 0.62M 0.27M
Bristol Myers Squibb BMY:US $ 2291M 160M
Eli Lilly And LLY:US $ 1430.8M 522.4M
Epizyme EPZM:US $ 2M 493K
GlaxoSmithKline GSK:LN 2822M 303M
Johnson & Johnson JNJ:US $ 7250M 317M
Karyopharm Therapeutics KPTI:US $ 589K 549K
MacroGenics MGNX:US 1.66M 1.64M
Merk MRK:US $ 3056M 14M
Nektar Therapeutics NKTR:US $ 5.31M 2.36M
Novartis NOVN:VX SF 3848M 94M
Novartis NVS:US $ 3848M 94M
Pfizer PFE:US $ 9931M 2939M
Regeneron Pharmaceuticals REGN:US $ 453.2M 240.5M
Takeda 4502:JP Y 275797M 34533M
Ultragenyx Pharmaceutical RARE:US $ 4.18M 1.04M
YTE INCY:US $ 34.47M 1.84M